Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness

BACKGROUND: Vedolizumab (VDZ) is a humanized monoclonal IgG1 antibody which inhibits leukocyte vascular adhesion and migration into the gastrointestinal tract through α4β7 integrin blockade. AIMS: We retrospectively assessed the 12-month, real-world efficacy and safety of VDZ as induction and mainte...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Can Assoc Gastroenterol
Main Authors: Zezos, Petros, Kabakchiev, Boyko, Weizman, Adam V, Nguyen, Geoffrey C, Narula, Neeraj, Croitoru, Kenneth, Steinhart, A Hillary, Silverberg, Mark S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7165264/
https://ncbi.nlm.nih.gov/pubmed/32328546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwy065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados